Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia
American Journal of Clinical Pathology · 02.11.2023 · 160 (5) · 490-499
DOI: 10.1093/ajcp/aqad077 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.07.2023. Verfasst von Joshua Tatarian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, US. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objectives
SRSF2 mutations are known to be associated with poor outcomes in myelodysplastic neoplasm, but studies on their prognostic impact on acute myeloid leukemia (AML) remain limited. In this retrospective study, we analyzed clinical and pathologic characteristics of patients with AML and correlated the outcomes with SRSF2 mutations.
Methods
We characterized the morphologic, immunophenotypic, molecular, and clinical findings in AML with mutated SRSF2 and compared them with SRSF2 wild-type (WT) myeloid neoplasms (MNs).
Results
Using next-generation sequencing, we identified 134 patients with MNs and SRSF2 mutations (85 with AML and 49 with MNs) in addition to 342 SRSF2-WT AMLs. Fifty-two (62%) patients with altered SRSF2 demonstrated a variable degree of morphologic dysplasia. The most frequent immunophenotypic aberrancies in SRSF2-mutant AML included diminished CD33 expression and overexpression of CD7, CD56, or CD123, similar to WT AML. More IDH1/2 (P = .015) and NPM1 (P = .002) mutations were seen in SRSF2-mutant AML than in SRSF2-mutant non-AML. Further, more IDH1/2, ASXL1, RUNX1, and STAG2 mutations were observed in SRSF2-mutant AML than in SRSF2-WT AML (P < .0001 to P = .001). Finally, patients with SRSF2-mutant AML showed a significantly worse overall survival (OS) than patients with SRSF2-WT AML (P < .0001), but this worse OS appeared to be rescued by allogeneic stem cell transplant (allo-SCT).
Conclusions
Acute myeloid leukemia with altered SRSF2 shows a variable degree of morphologic dysplasia without uniform immunophenotypic aberrancies. SRSF2 mutations appear to be independent poor prognostic factors, but allo-SCT has improved the clinical outcomes in patients with SRSF2-mutant AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, US.
- Division of Hematopathology, Department of Pathology, University of Utah, Salt Lake City, UT, US.
- Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS, US.
ORCID-Profile: Andrew K Godwin, Wei Cui
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIH HHS
- Kansas Institute for Precision Medicine Center
- National Institutes of Health
- National Cancer Institute
- Kansas Bioscience Authority
Zitieren
APA
Tatarian, J., Tupper, N., Li, P., Feusier, J., Abdo, M., Hyter, S., Gonzales, P. R., Zhang, D., Woodroof, J., Kelting, S., Godwin, A. K., & Cui, W. (2023). Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia. American Journal of Clinical Pathology, 160(5), 490-499. https://doi.org/10.1093/ajcp/aqad077
Vancouver
Tatarian J, Tupper N, Li P, Feusier J, Abdo M, Hyter S, et al. Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia. American Journal of Clinical Pathology. 2023;160(5):490-499. doi:10.1093/ajcp/aqad077
BibTeX
@article{Tatarian2023,
author = {Tatarian, Joshua and Tupper, Natalie and Li, Peng and Feusier, Julie and Abdo, Maryam and Hyter, Stephen and Gonzales, Patrick R and Zhang, Da and Woodroof, Janet and Kelting, Sarah and Godwin, Andrew K and Cui, Wei},
title = {Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2 -mutated acute myeloid leukemia},
journal = {American Journal of Clinical Pathology},
year = {2023},
volume = {160},
number = {5},
pages = {490--499},
doi = {10.1093/ajcp/aqad077}
}
EUVIMED